Why Gilead Sciences Shares Soared 10.6% in August
After Gilead Sciences (NASDAQ: GILD) surprised investors by announcing an $11.9 billion splash into cancer treatment, its shares jumped 10.6% in August according to S&P Global Market Intelligence.
Investors waiting to find out what Gilead Sciences would do with the tens of billions of dollars in its balance sheet were rewarded when the company announced it will be acquiring Kite Pharma (NASDAQ: KITE) in a deal valued at nearly $12 billion in cash.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Gilead Sciences Inc Aktie
119,14 €
-0,57 %
Die Gilead Sciences Inc Aktie ist ein klarer Community-Favorit: Nur Buy-Einschätzungen, keine Sell-Einschätzungen.
Ein positives, wenn auch nicht starkes, Potenzial für Gilead Sciences Inc mit einem Kursziel von 128 € im Vergleich zu 119.14 €.
